Link between Galectin-3 levels and post-operative atrial fibrillation after heart surgery
Association Between Galectin-3 and Post-operative AtrIal Fibrillation After Coronary Artery Bypass Graft
This study is trying to see if higher levels of a protein called Galectin-3 in the blood can help predict if patients will have heart rhythm problems after heart surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of Sao Paulo General Hospital Academic / other |
| Locations | 1 site (São Paulo, São Paulo) |
| Trial ID | NCT06768528 on ClinicalTrials.gov |
What this trial studies
This observational study aims to investigate the relationship between elevated levels of Galectin-3 and the incidence of post-operative atrial fibrillation in patients undergoing coronary artery bypass grafting (CABG). Participants will be enrolled during their pre-operative evaluation, and a blood sample will be collected within 24 hours before the surgery. The study will follow these patients for 12 months post-surgery to assess whether higher Galectin-3 levels correlate with worse outcomes, including other complications and major cardiovascular events.
Who should consider this trial
Good fit: Ideal candidates are patients scheduled for coronary artery bypass graft surgery.
Not a fit: Patients with renal dysfunction, severe left ventricular dysfunction, previous atrial fibrillation, or those undergoing concomitant valve surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a reliable biomarker for predicting the risk of post-operative atrial fibrillation, potentially improving patient management and outcomes.
How similar studies have performed: While the association of Galectin-3 with cardiovascular events has been explored, this specific approach to predicting post-operative atrial fibrillation is novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients undergoing coronary artery bypass graft surgery Exclusion Criteria: * Inability to sign the free and informed consent form * Renal dysfunction with estimated glomerular filtration rate less than 30ml / min / 1.73m² or dialysis therapy * Moderate to severe left ventricular dysfunction (ejection fraction \< 40%) * Patients with previous atrial fibrillation * Pregnancy * Concomitant valve surgery
Where this trial is running
São Paulo, São Paulo
- Instituto do Coração - Hospital das Clínicas - Faculdade de Medicina da Universidade de São Paulo — São Paulo, São Paulo, Brazil (Recruiting)
Study contacts
- Principal investigator: Leticia Carvalho — Instituto do Coração - HCFMUSP
- Study coordinator: Eduardo Lima
- Email: eduglima@yahoo.com.br
- Phone: + 5511 26615352
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.